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Context: Mutations in TAC3 and TACR3 (encoding neurokinin B and its receptor) have been iden-
tified in Turkish patients with idiopathic hypogonadotropic hypogonadism (IHH), but broader
populations have not yet been tested and genotype-phenotype correlations have not been
established.
Objective: A broad cohort of normosmic IHH probands was screened for mutations in TAC3/TACR3
to evaluate the prevalence of such mutations and define the genotype/phenotype relationships.
Design and Setting: The study consisted of sequencing of TAC3/TACR3, in vitro functional assays,
and neuroendocrine phenotyping conducted in tertiary care centers worldwide.
Patients or Other Participants: 345 probands, 18 family members, and 292 controls were studied.
Intervention: Reproductive phenotypes throughout reproductive life and before and after therapy
were examined.
Main Outcome Measure: Rare sequence variants in TAC3/TACR3 were detected.
Results: In TACR3, 19 probands harbored 13 distinct coding sequence rare nucleotide variants
[three nonsense mutations, six nonsynonymous, four synonymous (one predicted to affect splic-
ing)]. In TAC3, one homozygous single base pair deletion was identified, resulting in complete loss
of the neurokinin B decapeptide. Phenotypic information was available on 16 males and seven
females with coding sequence variants in TACR3/TAC3. Of the 16 males, 15 had microphallus; none
of the females had spontaneous thelarche. Seven of the 16 males and five of the seven females
were assessed after discontinuation of therapy; six of the seven males and four of the five females
demonstrated evidence for reversibility of their hypogonadotropism.
Conclusions: Mutations in the neurokinin B pathway are relatively common as causes of hypogo-
nadism. Although the neurokinin B pathway appears essential during early sexual development,
its importance in sustaining the integrity of the hypothalamic-pituitary-gonadal axis appears at-
tenuated over time. (J Clin Endocrinol Metab 95: 2857–2867, 2010)
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Abbreviations: EV, Empty vector; hpg, hypothalamic-pituitary-gonadal (axis); IHH, idio-
pathic hypogonadotropic hypogonadism; IP, inositol phosphate; nIHH, normosmic IHH;
NKB, neurokinin B; NK3-R, tachykinin receptor 3; T, testosterone.
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Humans with defects in GnRH secretion and/or actionwith resulting idiopathic hypogonadotropic hypo-
gonadism (IHH) have been instrumental in defining the
genetic control of this hormone. Human, animal, cellular,
and bioinformatic models have been integrated to identify
and understand the roles of genes affecting GnRH neuro-
nal migration [KAL1 (1), FGFR1 (2), FGF8 (3), NELF (4),
PROK2 (5–8), PROKR2 (6, 8)], GnRH secretory activity
[KISS1-R (9, 10), GNRH1 (11–13)], pituitary GnRH re-
sponsiveness [GNRHR (14)], and, in some cases, func-
tions yet to be clearly understood [CHD7 (15)]. The
newest proteins on this list are neurokinin B (NKB, en-
coded by TAC3) and its cognate G protein-coupled recep-
tor, NK3-R (encoded by TACR3) (16). NKB is a member
of the tachykinin superfamily of neuropeptides that in-
cludes substance P and neurokinin A (17). Mutations in
the genes encoding this ligand-receptor pair were recently
identified in a Turkish population of normosmic IHH
(nIHH) patients (16).
The mechanism(s) by which mutations in the NKB
pathway cause GnRH deficiency and IHH are not yet
clear.However,NKB is expressed in the sameneurons that
express kisspeptin, a member of the RF amide family of
proteins (sharing the common C-terminal sequence Arg-
Phe-NH2) (18, 19). Although mutations in the gene en-
coding kisspeptin (KISS1) have yet to be reported in hu-
mans with GnRH deficiency, mutations in the gene
encoding the kisspeptin receptor (KISS1-R or GPR54) have
been identified in nIHH probands as well as an individuals
with central precocious puberty (9, 10, 20–23). Kisspeptin
is a powerful stimulus for GnRH-induced LH secretion,
whereas paradoxically, NKB agonists appear to have an ex-
citatoryor inhibitoryeffectonGnRH-inducedgonadotropin
secretion in rodent models depending on gender and sex ste-
roid milieu (24–27). This variability in response to NKB
seems at odds with the discovery of loss of function muta-
tions in the NKB signaling pathway in hypogonadotropic
patients (16).
Because the original mutations in TAC3 and TACR3
were described only in Turkish patients, the goal of this
study was to examine the prevalence of TAC3 and TACR3
mutations in a much larger, international cohort of pa-
tients. Once putative mutations were identified, their func-
tional consequences were studied in vitro. The phenotypic
consequences of mutation-carrying patients were investi-
gated at several developmental windows including neo-
natal life, adolescence/early adulthood, and late adult-
hood (after sex steroid therapy) as evaluated by physical
examination, gonadotropin pulse pattern, and fertility
outcome.
The data from these studies demonstrate that function-
ally validated rare sequence variants within the tachykinin
pathway profoundly impact the functioning of the hypo-
thalamic-pituitary-gonadal (hpg) axis in late gestation.
However, the effect of these same mutations appears to
attenuate over time because a significant proportion of
patients carrying mutations exhibited partial or complete
reversal of their hypogonadotropism in adult life. These
data thus suggest that patients with genetic mutations in
this system may not require lifelong sex steroid replace-
ment and may be capable of spontaneous fertility. Finally,
these findings have importance for assembling the hierar-
chy of the various neuroendocrine and genetic determi-
nants of GnRH secretion in the human during both ado-
lescent puberty and the “mini-puberty” of neonatal life.
Patients and Methods
All study activities fell under research protocols approved by the
Massachusetts General Hospital Institutional Review Board.
Patient cohorts
The TAC3 and TACR3 genes were screened in two groups:
patients affected by nIHH, and prospectively recruited volun-
teers determined to have normal reproductive function by his-
tory and physical examination (192 Caucasians screened for
all coding exons, and 100 Brazilians screened only for five
nucleotide variants: G18D, I249V, Y256H, W275X, and
R295S). Patients were referred directly to the Reproductive En-
docrine Associates of Massachusetts General Hospital or the
Developmental Endocrinology Unit of the Clinical Hospital in
Sao Paulo, Brazil, for clinical evaluation, or they were referred by
their physicians to participate in genetic studies. Whenever pos-
sible, patients were interviewed by both a physician and a ge-
netics counselor using an Institutional Review Board-approved
questionnaire to obtain a thorough medical and family history.
The diagnosis of nIHH was based on the failure to undergo
normal sexual maturation by age 18 yr, low serum sex steroid
levels in the setting of inappropriately low or normal gonad-
otropin levels, and no other abnormality detected on cranial
imaging (28).
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das Clínicas da Faculdade de Medicina da Universidade de São Paulo 05403-900 Sa˜o Paulo, Brazil; Harvard Center for Reproductive Sciences and Division of Endocrinology, Diabetes,
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Olfactory testing employed the University of Pennsylvania
identification test whenever possible (29). A score of at least the
fifth centile based on sex and age was deemed normal. Of the 345
IHH patients who were screened, 107 were normosmic by ol-
factory testing, four were hyposmic, and the remaining 234 were
normosmic by self-report.
The 345 IHH probands represented a diverse racial mix: 213
were Caucasian (including 37 from Turkey), 25 were Asian, one
was American Indian/Alaskan native, 12 were African Ameri-
can, one was mixed native American/Caucasian, and 93 were
unknown [of these, 60 of 93 were Brazilian (30)] (Supplemental
Table 1, published on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org).
Of the nIHH probands, 248 were male, 95 were female,
and two were unknown. These ratios are consistent with pre-
viously published reports demonstrating a male predomi-
nance in nIHH (31).
Of the nIHH pedigrees, 89 were familial and 80 were spo-
radic, with the remaining unknown as to their mode of inheri-
tance. Of the familial cases, 43 could be classified as autosomal
dominant, 27 as autosomal recessive, and two as X-linked.
Clinical studies
Of the 345 IHH patients screened, 97 were admitted to the
General Clinical Research Center of Massachusetts General
Hospital for blood sampling every 10 min for 12–24 h to assess
endogenous GnRH-induced LH secretion as previously de-
scribed (32).
Clinical assays
Blood-sampling studies were performed over a 29-yr period;
therefore, two different immunoassay systems were used for the
measurement of LH. Originally, LH measurements were made
via RIA with a limit of detection of 0.8 IU/liter (33). Later, this
assay was switched to an automated microparticle enzyme im-
munoassay (AxSYM System; Abbott Laboratories, Abbott Park,
IL) with a limit of detection of 1.6 IU/liter. The microparticle
enzyme immunoassay was calibrated using the same reference
preparations as the RIA to make results comparable across data
sets. The data regarding the presence or absence of LH pulses are
based on the respective limits of detection of each system and
integrated by virtue of a common standard in both assays that
permitted interconversion.
Mutation analysis
Genomic DNA was extracted from peripheral blood leuko-
cytes. Probands were screened by PCR amplification of exon
segments and direct sequencing. The coding region of the TAC3
and TACR3 genes were amplified using PCR. The TAC3 gene
(chromosome 12; GenBank accession no. NM 013251) consists
of 10 exons. The TACR3 gene (chromosome 4; GenBank acces-
sion no. NM 001059) consists of five exons. Primers are outlined
in Supplemental Data 1. All amplified products were sequenced
using the AmpliTaq Dye Terminator Cycle Sequencing Kit and
an ABI PRISM 377 DNA sequencer (Perkin-Elmer Corp., Foster
City, CA). All sequence variations were found on both strands
and confirmed in a separate PCR. All nucleotide changes were
assessed for their presence in the National Center for Biotech-
nology Information database of single nucleotide polymor-
phisms, the expressed sequence tags database, and among con-
trol alleles.
Of the 345 probands in the cohort, 284 were also screened for
mutations in genes known to be involved in IHH, including
FGFR1 (n 5 332), KISS1-R (n 5 336), NELF (n 5 274),
GNRHR (n 5 343), FGF8 (n 5 332), GNRH1 (n 5 200), KAL1
(n 5 334), PROK2 (n 5 330), and PROKR2 (n 5 330).
Functional studies
African green monkey kidney fibroblast cells (COS-7 cells)
were transiently transfected with 0.5 mg of either WT, G18D,
I249V, Y256H, R295S, or Y315C NK3-R or empty vector (EV)
(pcDNA3.11) using GenePORTER Transfection Reagent (Gene
TherapySystems,SanDiego,CA).GenerationofNK3-Rmutations
and inositol phosphate (IP) assays are described in Supplemental
Data 2.
Results
IHH and TACR3
Ethnic and gender distribution
Rare nucleotide variants in TACR3 were identified in
19 of 345 nIHH probands for a total prevalence of 5.5%.
When the frequency of variants was examined in different
racial subgroups, nucleotide changes were identified in 10
of 213 Caucasian probands (4.7%; four of the 10 pro-
bands were Turkish, for a 10.8% frequency in that ethnic
subgroup), two of 25 were Asian probands (8%), and one
of 12 was an African-American proband (8.3%) (Table
S1). In probands where the racial designation was uncer-
tain, one of 11 Hispanic probands (9%), four of 60 Bra-
zilian probands (6.7%) (30), and one additional individ-
ual also harbored variants (Supplemental Table 1). Rare
nucleotide variants were identified in 15 of 247 males
(6.1%) and four of 95 females (4.2%) and thus occurred
at approximately equal frequency in both genders.
Variants
Of the 345 nIHH probands, 19 were found to harbor
13 distinct coding sequence nucleotide variants in TACR3
that were not observed in 292 controls (Table 1; also see
Fig. 2). With the exception of P353S, which had previously
been reported in the Turkish population (16), all other
variants were novel. Three of the 13 variants were non-
sense mutations (S27X, W280X, W275X); six of 13 vari-
ants were nonsynonymous (i.e. changing the amino acid:
G18D, I249V, Y256H, R295S, Y315C, P353S); and the
remaining four variants were synonymous (i.e. not chang-
ing the amino acid: L58L, V98V, T246T, S448S). How-
ever, the homozygous G.A transition underlying T246T
occurred in the last base pair of exon 2 and was predicted
to affect splicing (NNSPLICE 0.9). Of the nonsense, non-
synonymous, and putative splice site changes (n 5 10), six
were homozygous [S27X, W275X (present in three pro-
bands), Y256H, Y315C, P353S, T246T], and five variants
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were heterozygous [G18D, W208X, I249V, W275X
(present in four probands), R295S].
Of the eight probands bearing homozygous TACR3
variants, three were familial (only one of the three ap-
peared to have an autosomal recessive mode of inheri-
tance), three were sporadic, and two were unknown. Of
the 11 probands bearing heterozygous (n 5 10) or possible
compound heterozygous (n 5 1) variants, five were fa-
milial (one dominant, two recessive, and two unknown),
four were sporadic, and two were unknown.
In familial cases, the identified nucleotide variants did
not arise de novo but rather were present in at least one
parent and all family members who were affected by IHH
and whose DNA was available (Fig. 1). This observation
suggests that TACR3 does not undergo frequent sponta-
neous mutagenesis.
Functional studies
In WT NK3-R transfected cells, NKB caused a 16.7 6
3.9-fold induction of IP production; in contrast, cells
transfected with EV failed to show any
IP induction. Y256H, R295S, and Y315C
NK-3R variants showed complete loss of
function, with IP induction of 1.2 6 0.2-fold,
3.2 6 0.6-fold, and 1.7 6 0.5-fold, respec-
tively, over unstimulated levels. In contrast,
cells transfected with the G18D or I249V
NK3-R variant had a 13.5 6 3.5-fold and
16.1 6 4.4-fold IP induction, respectively, in
response to 1027 M NKB, not significantly dif-
ferent from cells transfected with WT NK3-R
(Fig. 2).
Clinical phenotypes
Probands carrying rare variants in TACR3
exhibited a broad range of phenotypes. Of
males carrying coding sequence variants in
TACR3 and in whom information was avail-
able (n 5 15 probands and one family mem-
ber), 15 of 16 or 94% had microphallus
[stretched penile length of less than 10.5 cm
(34)] as assessed by questionnaire or physical
examination at first presentation (in most
cases) (Table 2). Surprisingly, despite this high
prevalence of microphallus, only two pro-
bands (no. 7 and no. 13) had cryptorchidism.
Testes size was generally small but did range
from 1–12 ml, suggesting that some probands
had undergone partial sexual maturation (35)
(Table 2). Of females carrying sequence vari-
ants in TACR3 and in whom information was
available (n 5 3), none had spontaneous the-
larche or menarche (Table 3).
Probands were also evaluated after treatment was dis-
continued (most commonly sex steroids). In striking con-
trast to the signs of severe hypogonadotropism that accom-
panied their initial presentation (pre treatment), several
probands with TACR3 mutations showed evidence for
spontaneous activity of their hpg axis post treatment in
adulthood. Three males [no. 6 with W275X/N, no. 8 with
W275X/N, no. 12 with Y256H/Y256H (functionally val-
idated)] exhibited significant increases in testicular vol-
ume while on androgens, suggestive of endogenous go-
nadotropin stimulation of Sertoli cell complement (Table
2). Notably, no. 6 and no. 8 also achieved fertility in the
absence of gonadotropin/GnRH therapy.
Four male probands underwent blood sampling every
10 min to assess endogenous GnRH-induced LH pulsa-
tility (Table 2 and Fig. 3). Within this group, no. 12
[Y256H/Y256H (functionally validated)] had 5-ml testes
and a testosterone (T) level of 65 ng/dl pre treatment. After
androgen treatment, he had 12-ml testes, T level of 222
C
A B 
E
D
FIG. 1. Pedigrees of familial cases of TACR3 and TAC3 mutations. With only one
exception, all the affected family members had the same change as their respective
probands. A, Proband 4; B, proband 7; C, proband 2; D, proband 11; E, proband 20.
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ng/dl, and four LH pulses during 12 h of blood sampling
every 10 min. Similarly, patient 16 (V98V/N) had a T level
of 16 ng/dl before treatment but 246 ng/dl after treatment,
accompanied by five LH pulses in 12 h. Proband 6
(W275X/N) had a complete absence of GnRH-induced
LH pulses before starting sex steroid therapy; after treat-
ment, two LH pulses were detectable. Despite this modest
change in his neuroendocrine profile, years later, this pa-
tient conceived a child in the absence of GnRH or gonad-
otropin therapy (genetic paternity not confirmed). Pro-
band 7 (W275X/N) also had no LH pulses before
androgen therapy but after treatment demonstrated ro-
bust LH pulses (although his T levels remained subnor-
mal) (Table 2 and Fig. 3). Notably, one of the brothers of
proband 7 (7b) who carried the same W275X mutation
demonstrated an active LH pattern on his post treatment
sampling study but with normal T levels (Figs. 1B and 3
and Table 2). Another brother with IHH also showed a
“normalized” hpg axis after treatment
based on hormone levels, but no DNA
is available to confirm his TACR3 ge-
notype (Fig. 1B).
IHH and TAC3
For TAC3, one female proband
from a consanguineous family (no. 20)
was found to harbor a homozygous
frameshift mutation (c.G60del) leading
to a premature termination codon in
the precursor upstream of the NKB de-
capeptide (Supplemental Fig. 1). After
treatment with sex steroids, this indi-
vidual conceived a child without fertil-
ity medications, but she subsequently
suffered an early pregnancy loss. One of
her sisters carrying the same homozy-
gous mutation (no. 20b) also conceived
spontaneously, and she carried the
pregnancy to term (Table 3 and Fig. 1).
Sister 20c has not conceived but has
regular menstrual cycles (Table 3 and
Fig. 1). Sister 20d has had a positive
withdrawal bleed to a progesterone
challenge but does not cycle spontane-
ously (Table 3 and Fig. 1).
Discussion
This report focuses on reproductive
phenotypes before and after sex steroid
therapy in hypogonadotropic patients
with rare nucleotide variants in the
NKB pathway. Although information regarding the pro-
bands and family members comes from several different
sources with variable depth of phenotyping, therapies,
and intensity of follow-up, two striking biological features
emerge. Most males carrying TACR3 variants for whom
physical examination evidence was available (94%) had
microphallus identified either neonatally or later in life.
This frequency stands in sharp contrast to an 8% preva-
lence of microphallus in an nIHH cohort (n 5 42) selected
without consideration of genetic etiology (35). Because
phallic growth is strongly influenced by the integrity of the
in utero activity of the hpg axis in late gestation (36), this
consistent presence of microphallus suggests that NKB-
stimulated signaling plays an important role as a driver of
GnRH secretory activity during this critical window of
development. Second, the majority of patients who were
assessed longitudinally after discontinuation of sex steroid
T
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FIG. 2. A, Schematic of mutations in NK3-R. B, Effects of mutations in TACR3 on NKB-
mediated activation of signal transduction. COS-7 cells transfected with wild-type (WT),
G18D, I249V, Y256H, R295S, and Y315C NK3-R or EV were treated with NKB (1027 M) for
1 h. A significant increase in IP accumulation occurred in cells transfected with WT, G18D, or
I249V NK3-R. In contrast, there was a marked reduction in NKB-stimulated IP production in cells
transfected with Y256H, R295S, or Y315C NK3-R, or with EV. a, b, and c denote significantly
different fold increases in IP accumulation.
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therapy exhibited evidence of spontaneous partial or com-
plete recovery of their reproductive axis (10 of 12 or 83%),
as determined by increases in LH pulsatility, T, testicular
volume, the presence of withdrawal bleeding, spontane-
ous menstrual cycles, and/or spontaneous pregnancy (10
individuals with rare sequence variants: 9 of 10 with ter-
mination, frameshift, or functionally validated mutations;
and one of 10 with heterozygous synonymous change).
Although determining the true incidence of amelioration
of IHH is limited by the difficulty of assessing patients off
therapy, the high prevalence of reversal reported here
stands in sharp distinction to the much lower reported
incidence of recovery from GnRH deficiency in a patient
cohort bearing a variety of genetic mutations (;10%)
(28). Thus, TAC3/TACR3 genetic defects may portend
future prognosis in IHH and foreshadow the possibility of
discontinuing sex steroid or gonadotropin therapy later in
life. More importantly, perhaps, this striking phenotype
strongly suggests that the role of the NKB system in GnRH
secretion may be less critical in adult life than during late
gestation and the early neonatal period. This finding is in
contrast to patients with DAX1 mutations causing adre-
nal hypoplasia congenita (IHH and adrenal insufficiency),
who can have active hpg axes in neonatal life followed by
adolescent hypogonadotropism (37). Moreover, the
TAC3/TACR3 phenotype appears to be distinct from the
phenotypes associated with another secretory product of
the same neurons, kisspeptin, and its cognate receptor,
KISS1-R, where reversal of IHH has not yet been de-
scribed. Of course, this latter point must be interpreted
with caution because the number of well-studied muta-
tions in the KISS1/KISS1-R system is much
smaller at this time (9, 10, 20, 21).
Nonsense mutations in the ligand (TAC3)
and receptor (TACR3) provide an important
opportunity to examine the most severe dos-
ing of gene impairment, thereby allowing a
contrast of phenotypic severity as well as a
contrast between the two sexes. For example,
two females with a homozygous frameshift
mutation in TAC3 conceived spontaneously.
Another continued having spontaneous reg-
ular menstrual cycles after discontinuation of
sex steroid treatment. Because the homozy-
gous TAC3 mutation led to a complete ab-
sence of peptide, these patients demonstrate
that the ligand, NKB, is dispensable for
GnRH synthesis and secretion during the
adult period. Because the tachykinin path-
way is already well known to be promiscu-
ous, other tachykinins, or even completely
different ligands might compensate for their
absence of NKB (17).
In parallel to this ligand mutation, four men had ho-
mozygous nonsense mutations in TACR3. Although pa-
tient 3 (homozygous W275X) was born with a microphal-
lus, no follow-up is available to determine whether his
hypogonadal state persisted or showed evidence for re-
covery later in life. Similarly, little follow-up information
is available on the other male homozygous patients: no. 1
(S27X/S27X), no. 4 and no. 5 (W275X/W275X), as well
as no. 17 (with the presumed homozygous splice site mu-
tation T246T/T246T). However, proband 12 (Y256H/
Y256H; validated loss-of-function in vitro) presented at
age 21 with a history of microphallus and a hypogonadal
T level (65 ng/dl) but subsequently demonstrated robust
LH pulses off therapy with T levels of 222 ng/dl later in
adulthood. This observation suggests that patients with
markedly abnormal signaling through the NKB receptor
can still achieve robust GnRH synthesis and secretion dur-
ing adulthood.
Using traditional Mendelian principles, patients bear-
ing heterozygous mutations in autosomal recessively in-
herited genes, such as those encoding NKB and its recep-
tor, would not be predicted to manifest a disease
phenotype. However, heterozygous mutations in the gene
encoding another G protein-coupled receptor [prokineti-
cin 2 receptor (PROKR2)] have now been reported as
contributors to the IHH disease phenotype, either alone or
in the presence of heterozygous mutations in other as-yet-
to-be-identified genes/pathways (8). Thus, patients with
homozygous nonsense mutations in TACR3 might be hy-
pothesized to have more severe phenotypes than those
FIG. 3. Blood sampling every 10 min regarding reversal probands. Left, Studies before
treatment. Right, Studies after discontinuation of treatment. *, T value represents a
single blood sample taken within 5 months of the sampling study.
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bearing heterozygous mutations. Three probands with ho-
mozygous W275X presented with microphallus; how-
ever, three of four men bearing heterozygous nonsense
mutations also had microphallus, suggesting that despite
a smaller number of intact TACR3 alleles, the severity of
early androgen deficiency was comparable. Importantly,
whereas the vast majority of the patients with mutations
in this series were screened for mutations in the other
genes currently known to cause IHH, strikingly only one
rare heterozygous variant (13) was identified in another
gene (proband 17, bearing heterozygous T58S in GnRH1)
(Table 1).
Despite the number of mutations identified in the NKB
pathway, our knowledge of how this ligand/receptor pair
influences GnRH secretion remains incomplete. In ro-
dents and sheep, NKB and its receptor are coexpressed in
neurons that express kisspeptin and dynorphin (18, 19),
raising the possibility of neurokinins acting indirectly to
modulate GnRH secretion. Like many other genes in-
volved in the pathogenesis of GnRH deficiency, NKB and
its receptor are also expressed in various other organs
(uterus and ovary) (38, 39), opening the possibility that
mutations in this pathway can act at multiple levels of the
hpg axis to cause dysfunction. In contrast to patients with
nIHH, mice with targeted deletions of Tacr3, at least in the
strains tested to date, do not have gross reproductive de-
fects (40), and mice in which the TAC3-equivalent gene
Tac2 has been selectively deleted have yet to be reported.
Mutations in the NKB system are relatively common as
causes of hypogonadism, occurring in more than 5% of a
nIHH population that spans several ethnic groups. Al-
though additional studies will help to illuminate the biol-
ogy and interactions of the neurokinin pathway, the severe
hypogonadotropism observed during early neonatal life in
patients with mutations in the ligand/receptor pair juxta-
posed against later markers of recovery suggests that NKB
and its receptor play disparate roles in different windows
of reproductive development.
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